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Abstract 
Aims: To retrospectively evaluate agreement between modified RECIST criteria 
(mRECIST) assessed at Computed Tomography (CT) and pathology in a large series of 
patients with hepatocellular carcinoma (HCC) who were transplanted after transarterial 
chemoembolization (TACE). 
Materials and Methods: From January 1996 to December 2010, 178 patients 
(M/F=155/23; mean age 55.8±6.3 years) with HCC underwent TACE followed by liver 
transplantation (LT). Two blinded independent readers retrospectively reviewed CT 
examinations, performed in the interval between TACE and LT, to assess tumor 
response to TACE according to mRECIST. On the explanted livers, percentage of 
tumor necrosis was pathologically classified as 100%, 90-99%, 50-90%, <50% and 0%. 
Results: At latest CT examination, the objective response rate was 77.5% (138/178), 
with 86 cases (48.3%) of complete response (CR). A good intra- (k=0.75 and 0.86) and 
inter-observer (k=0.81) agreement was obtained. Out of 302 nodules, sensitivity and 
specificity of CT in detecting complete necrosis were 87.5% and 68.9%, respectively.  
On a per-patient basis, agreement between mRECIST and pathology was obtained in 
119 patients (66.9%), with 20 cases (11.2%) of underestimation and 39 cases (21.9%) of 
overestimation of tumor response at CT. The majority of overestimations (26/39, 
66.7%) consisted of patients with CR and 90-99% necrosis. CT sensitivity and 
specificity in differentiating between responders and non-responders were 92.3% and 
82.9%, respectively. 
Conclusions: CT can overestimate tumor response, by missing minimal residual viable 
tumor. Nonetheless, mRECIST criteria assessed at CT after TACE are reproducible and 
reliable, with high accuracy in differentiating responders and non-responders.  
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Introduction 
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and its 
incidence is increasing worldwide [1]. Liver transplantation (LT) represents the only 
curative option for both tumor and underlying cirrhosis in properly selected patients 
[2,3]; however, limited organ availability and late diagnosis reduce the chances for LT. 
Loco-regional therapies, such as percutaneous ablation and transarterial 
chemoembolization (TACE), represent valid options to improve survival in non-surgical 
patients [2,4,5], as well as to bridge the patients or to downstage the tumor allowing 
transplantation [6-8]. The increased use of loco-regional therapies in the treatment of 
HCC has raised the issue of the best modality to measure response rate. In fact, the 
World Health Organization (WHO) criteria (which measure change in tumor size) 
underestimate the actual response rate [9]; thus, they were amended in year 2000 by a 
panel of experts convened by the European Association for the Study of the Liver 
(EASL) to take into account treatment-induced tumor necrosis [10]. More recently, the 
Response Evaluation Criteria in Solid Tumors (RECIST) guideline was proposed as a 
method for measuring treatment response based on tumor shrinkage [11-12]. However, 
RECIST criteria can be misleading when applied to molecular-targeted therapies or 
loco-regional therapies in HCC [13]. Therefore, recent guidelines proposed the EASL 
criteria, also called modified RECIST (mRECIST) criteria, as valid means to assess 
HCC response to treatment, by recognizing residual viable tumor [14,15]. However, so 
far, there are only few data regarding the accuracy of mRECIST compared to the gold 
standard, represented by pathologic studies of explanted livers.  
Purpose of this retrospective, single-center study was to evaluate agreement between 
mRECIST and pathologic results in a large series of HCC patients who were 
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transplanted after TACE. 
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Materials and methods 
This is a single-institution retrospective study of consecutive HCC patients who were 
treated by TACE followed by LT from January 1996 to December 2010. The study 
protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki; 
informed written consent was obtained from each patient. 
We searched our database collecting all the patients who were transplanted for HCC 
after TACE from January 1996 to December 2010 (220 patients). We excluded patients 
who did not perform Computed Tomography (CT) examination of the abdomen in the 
time interval between TACE and LT. Our final study population included 178 patients 
(M/F=155/23; mean age 55.8±6.3 years, range 36-68 years). The mean tumor nodules 
number was 2±1.3 (range 1-6) with a mean size of 46.3±27.1 mm (range 10-130 mm). 
TACE protocol 
Digital Subtraction Angiography (Multistar, Siemens, Erlangen, Germany) of hepatic 
and mesenteric arteries was performed immediately before TACE to map vascular liver 
anatomy, to evaluate the presence of arterio-venous shunts and to identify arterial 
feeders of the tumor. All procedures were performed under local analgesia, antibiotic 
prophylaxis (ceftriaxone, 1g/die at day 0, +1 and +2) and antiemetic drugs. TACE was 
performed by selective catheterization of the hepatic segmental arteries supplying the 
lesions, using either 5-F catheters or 3-F coaxial microcatheters.   
In patients treated by Lipiodol-TACE, a mixture of iodized oil (Lipiodol UltraFluid; 
Laboratories Guerbet, Aulnay-sous-Bois, France) and doxorubicin hydrochloride 
(Adriblastina; Pfizer Italia srl, Borgo San Michele, Italy) was injected, followed by 
selective arterial embolization using an emulsion of grated gelatin sponge particles 
(Spongostan Standard; Johnson and Johnson Medical Limited, Gargrave, Skipton, UK). 
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The amount of administered iodized oil (10-20 mL; mean 17 mL) and doxorubicin (50-
75 mg; mean 55.0 mg) was decided on the basis of number and diameter of lesions.  
The drug-eluting beads (DEB)-TACE protocol consisted in the superselective injection 
of 2-4 ml of DC Beads 100-300 µm (Biocompatibles UK, Farnham, Surrey, UK) loaded 
with doxorubicin (50 mg per vial; range 25-100 mg; mean 55 mg). The beads were 
mixed with a volume of non-ionic contrast medium prior to delivery, using a ratio of 
1:3. 
TACE was considered technically successful when the target lesions were fully 
embolized, as demonstrated by selective angiography performed at completion of the 
procedure.  
CT follow-up 
After TACE, CT was scheduled at 1 month and every 3 months thereafter. 
CT protocol included a non-enhanced acquisition followed by triphasic (arterial, venous 
and delayed phases) acquisition after intravenous injection of iodized contrast medium 
(120-130 mL) at a flow rate of 3-4mL/sec. The protocol varied according to the CT 
equipment available at the time of the procedure (Table 1). 
Image analysis 
CT examinations performed after TACE were collected; if patients underwent multiple 
CT examinations in the interval between TACE and LT, the examination performed at 
the time point closest to the time of transplantation was reviewed. 
Two independent radiologists (6 and 12 years of experience, respectively), blinded to 
the histopathology findings, were asked to review preprocedural and post-TACE CT 
images and assess tumor response according to mRECIST [14,15]. Complete response 
(CR) was defined as the disappearance of any intratumoral arterial enhancement in all 
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target lesions; partial response (PR) was defined as ≥30% decrease in the sum of 
diameters of viable portion of the target lesions, with the baseline sum of the diameters 
of target lesions as a reference. Progressive disease (PD) was considered as a ≥20% 
increase in the sum of the diameters of viable target lesions, with the lowest sum of the 
diameters of viable target lesions recorded since the treatment started as a reference. PD 
also included the presence of new lesions, at least 1 cm in size, with the typical 
enhancement pattern for HCC. Finally, stable disease (SD) was defined as any cases 
that did not qualify for CR, PR or PD.  
Viable tumor was defined as contrast uptake in the arterial phase and washout in portal 
venous and/or late venous phases. After Lipiodol-TACE, comparison of the non-
enhanced and the arterial phase images was required to discriminate between iodized oil 
and contrast uptake. Any area of absent Lipiodol uptake was regarded as suspicious for 
the presence of viable tumor. In those areas quantitative measurements were obtained 
placing a Region-of-interest (ROI) in all phase images and using the criteria proposed 
by Kim et al [16]: a difference in attenuation value of at least 20 HU between the 
unenhanced phase and at least one of the contrast-enhanced phases was considered 
indicative for viable tumor.  
Each reader performed the image evaluation twice, after an interval of at least 7 days, to 
assess intra-observer variability. 
Reference standard: Histopathology Analysis 
After LT, gross and fine histological analysis of the explanted livers was performed by 
two experienced pathologists (20 and 15 years of experience, respectively). Gross 
examination of the livers was performed after cutting the liver into thin slices (5-10 mm 
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thickness) in parallel to the plane of the round ligament; routine hematoxylin and eosin 
staining was used to prepare the slides. The precise location and size of any intrahepatic 
nodule were recorded. Each macroscopically identified nodule was microscopically 
analyzed and classified. The treated lesions were examined for the presence of viable 
tumor tissue, and percentage of necrosis was classified as: 100% (absence of any viable 
tissue); 90-99% (persistence of minimal viable tissue); 50-90% (significant necrosis); 
<50% (minimal necrosis); 0% (absent necrosis).  
Statistical analysis 
Statistical analysis was performed with SAS software (SAS Institute, Cary, NC). 
Data were analyzed via descriptive statistics (mean and standard deviation, SD) and 
compared by the Chi-square or Fisher exact tests (categorical data), as appropriate, and 
paired t test (continuous data). 
Intra- and inter-observer agreement was calculated by the weighted kappa (k) test. 
A nodule-by-nodule analysis was conducted to assess sensitivity, specificity, positive 
predictive value (PPV), negative predictive value (NPV), and accuracy of CT in the 
prediction of complete necrosis.  
On a patient-by-patient analysis, agreement between mRECIST and histopathology 
findings was evaluated by the weighted kappa (k) test, assuming the correspondence 
between 100% necrosis and CR, 50-99% necrosis and PR, <50% necrosis and SD/PD. 
A P value of less than 0.05 was considered as statistically significant. 
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Results 
Out of the entire series, 156 patients (87.6%) underwent Lipiodol-TACE, whereas 22 
cases (12.4%) were treated by DEB-TACE; the latter group had a significantly lower 
number of tumor nodules (mean 1.4 versus 2.1, P=.03). 
The mean interval between TACE and LT was 168 ± 120 days (range, 32-802), whereas 
the mean interval between CT and LT was 65 ± 57.4 days (range, 1-468). 
Histopathology findings 
The analysis of the explanted livers revealed the presence of complete necrosis in 60 
patients (33.7%), whereas minimal residual viable tumor was depicted in 38 livers 
(21.4%) (Table 2). 
The extent of necrosis was significantly affected by the tumor nodules’ number and 
size, while it was not related to other variables, such as the interval between TACE and 
LT or the TACE protocol. 
CT findings 
Intra-observer agreement was good (k=0.75 for Observer 1 and k=0.86 for Observer 2); 
inter-observer agreement was rated as good to excellent (k=0.81). 
The objective response rate at CT was 77.5%, with 48.3% CR (86/178 patients), 29.2% 
PR (52/178 patients), 12.9% SD (23/178 patients) and 9.6% PD (17/178 patients). Mean 
tumor size and number of nodules were significantly lower in the CR group (P=.01 and 
P=.0007, respectively). 
Nodule-by-nodule analysis 
Forty-eight nodules (in 34 patients) diagnosed as HCC at CT were not confirmed at 
pathology; conversely, 24 nodules (in 16 patients) identified on the explants were 
missed at CT examination. 
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Out of a total of 302 nodules (mean size 24.6 ±14.5 mm, range 10-80mm) detected at 
CT and confirmed at pathology, 157 lesions (52%) were considered completely necrotic 
at CT (Table 3). Sensitivity, specificity, PPV and NPV in detecting complete necrosis at 
CT were 87.5%, 68.9%, 62.4%, 90.3%, respectively, with 75.8% diagnostic accuracy 
(Figure 1). 
The agreement between CT and pathologic findings was not significantly affected by 
variables, such as nodules’ size, TACE protocol, CT equipment, TACE-LT interval and 
CT-LT interval. 
Patient-by-patient analysis 
Comparison between mRECIST and tumor necrosis is presented in Table 4. Overall 
agreement was obtained in 119 patients (66.9%), with 20 cases (11.2%) of 
underestimation and 39 cases (21.9%) of overestimation of tumor response at CT. These 
results were not significantly influenced by variables such as TACE-LT interval, CT-LT 
interval, TACE protocol and CT equipment. 
The majority of overestimations (26/39, 66.7%) consisted of patients classified as CR, 
who presented minimal residual viable tumor (>90% necrosis) at pathology (Figure 2). 
When comparing responders with non-responders (Table 5), CT accuracy reached 
90.4%, with 92.3% sensitivity, 82.9% specificity, 95.7% PPV and 72.5% NPV.  
PD was due to the detection of new lesions in 9/17 patients. All of these patients were 
classified as having 50-90% necrosis at pathology (Figure 2). When excluding these 
patients from the analysis of the results, CT accuracy resulted to be 95.3%, with 98.5% 
sensitivity, 82.9% specificity, 95.7% PPV and 93.5% NPV. 
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Discussion 
Measurement of tumor response after treatment is of major importance for patients’ 
management in clinical practice, as well as for evaluating the outcomes of clinical trials 
[14]. 
The development of loco-regional therapies in HCC has raised the issue on how to 
assess radiological tumor response. In fact, the limitations of WHO and RECIST 
criteria, which are based on tumor shrinkage, have been widely demonstrated [13]. 
Thus, mRECIST criteria have been introduced to standardize radiological assessment of 
tumor response in HCC, based on estimation of tumor necrosis [10,14,15]. 
There are only few studies evaluating the accuracy of mRECIST compared to 
pathologic data, which pointed out the limitations of mRECIST in terms of specificity 
in detecting tumor necrosis [17-19]. Riaz et al proposed the use of the product of WHO 
and EASL (mRECIST) criteria to increase diagnostic accuracy [19]. However, this type 
of evaluation seems to be a little more complex and its widespread application may 
have some limitations. 
The present study reports the results of large cohort of patients who were transplanted 
after TACE from 1996 to 2010.  
In our series, complete necrosis was achieved in 33.7% of the patients and 37% of the 
nodules, whereas 58% of the treated nodules showed >90% necrosis. This was 
comparable to previous reports on chemoembolization [8,17,20]. As expected, 
pathologic necrosis was significantly higher when the tumor extension was more 
limited. On the other hand, necrosis was not influenced by the time elapsed between 
TACE and LT [17]; also, TACE protocol did not influence tumor necrosis [21], 
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although the number of patients treated by DEB-TACE was more limited compared to 
the number of patients who underwent Lipiodol-TACE.  
The estimation of tumor necrosis and the recognition of residual viable enhancing tumor 
can be troublesome, particularly after Lipiodol-TACE. Previous studies [22] have 
demonstrated the relatively low accuracy of CT in recognizing residual viable tumor 
after Lipiodol-TACE, due to the artifacts created by the dense accumulation of 
Lipiodol. In a series of 20 patients, Kloeckner et al. showed that, compared to Magnetic 
Resonance (MR), CT overestimated the extension of necrosis in 4/13 (30.8%) patients 
after Lipiodol-TACE, whereas the results were comparable after DEB-TACE [23]. 
Thus, MR has been proposed as a more accurate way to evaluate tumor response after 
TACE, with the potential added value of functional imaging and image post-processing 
[24-26]. On the other hand, MR has some drawbacks: costs, availability, duration and 
complexity of the examination, patient’s compliance and possible contraindications. 
Because of these drawbacks, in our department CT is used as first-line imaging 
modality after HCC treatment, performing MR in case of unconfident findings. 
Our results, based on over 300 nodules, confirm that CT may overestimate tumor 
necrosis, with a relatively low specificity (62%), yet a high sensitivity (over 87%) and 
an acceptable overall accuracy (75%). In a previous study carried out by Riaz et al. on 
35 lesions treated by Lipiodol-TACE, specificity raised up to 82% when using MR for 
follow-up [17]. Of interest, we could not find any significant difference in CT accuracy 
when comparing Lipiodol-TACE to DEB-TACE, although disparity in numbers has to 
be taken into consideration. 
CT accuracy in detecting tumor necrosis seems not to be influenced by some possible 
variables, such as tumor extension, interval between CT and LT and, most of all, CT 
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equipment. The latter result needs further interpretation. In fact, the improvement in CT 
technology over the last decades should have played a role in improving CT accuracy. 
However, this is not the case, probably because the operators’ training and specific 
experience play a more important role than the adopted technology. Indeed, intra-
observer variability was a little lower for Observer 2 (12 years of experience) compared 
to Observer 1 (6 years of experience). Nonetheless, mRECIST criteria are reproducible, 
with good intra- and inter-observer agreements.  
On a per-patient basis, the agreement between CT and pathology was acceptable 
(almost 70% of patients). We observed cases of both overestimation and 
underestimation of tumor response. The underestimation was mostly due to the presence 
of inhomogeneous Lipiodol uptake and apparent arterial enhancement; in fact, all the 
areas of inhomogeneous Lipiodol accumulation were regarded as possible areas of 
residual viable tumor [27]. To reduce response underestimation, viable tumor should be 
defined on the basis of arterial enhancement (wash-in) associated to wash-out in the 
portal or delayed phase, as for the pre-procedural diagnostic work-up for HCC. In fact, 
in our experience, arterial enhancement alone can be caused by several conditions other 
than HCC, for instance arterio-portal shunts, leading to false positive results.   
Overestimation of tumor response was mainly due to minimal residual tumor cells 
within the treated nodules. In fact, almost 30% of the nodules that were classified as CR 
showed 90-99% necrosis at pathology. Whether MR could detect this minimal residual 
viable tumor has to be demonstrated. Accordingly, further studies are required to 
evaluate the clinical impact of 90-99% necrosis, in terms of post-LT survival and tumor 
recurrence, as well as in terms of need for further treatments in non-surgical patients. 
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Previous studies have demonstrated that response to loco-regional therapies may be a 
strong prognostic indicator in surgical and non-surgical patients [28-30]. In a series of 
patients unfit for LT, Riaz A et al. showed that survival is significantly higher after 
partial or complete response compared to progressive disease or stable disease, 
following either TACE or radioembolization [30]. Thus, the accuracy of a radiological 
method should be focused on its ability in differentiating between responders and non-
responders. In this setting, CT accuracy in our series was 90%, with high sensitivity and 
specificity. Specificity and NPV further increased when excluding those patients who 
were classified as PD for the presence of new untreated lesions (n=9). All of these 
patients had over 50% necrosis at pathology, since the treated nodules were completely 
or almost completely necrotic, associated with smaller new untreated and non-necrotic 
lesions. 
Our study has some limitations. We included patients treated over a wide period of 
time, with modifications in the technical approach as well as in the imaging procedures. 
In fact, different CT equipments and protocols were used over the years, although this 
seems not to have affected our results. The comparison between CT and pathology is 
retrospective; we could not precisely quantify percentage of necrosis in each nodule and 
we classified patients in a less accurate way. 
Despite these limitations, our results, drawn from a relatively large population, show 
that mRECIST criteria after TACE are reproducible and reliable, even by CT. MR can 
be reserved to patients with unconfident or inconclusive CT findings, thus reducing the 
costs of follow up. Operators’ training is demanding to accurately assess tumor response 
and reduce the rate of CT overestimation. Despite this overestimation, CT accurately 
  
15 
discriminates between responders and non-responders, which plays a major role in 
defining patients’ prognosis and clinical management.  
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Table 1 – Acquisition protocol according to CT equipment 
 
Scan delay CT Years n. of 
patients 
Slice 
thickness 
Spacing 
Arterial Venous Delayed 
Single 
slice 
1996- 
2000 
47 
(26.4%) 
7 mm 5 mm 30 sec 80 sec 180 sec 
4-slice 
MDCT 
2001- 
2007 
80 
(44.9%) 
5 mm 2.5 mm 30 sec 75 sec 170 sec 
64-slice 
MDCT 
2008-
2010 
51 
(28.7%) 
2.5 mm 2.5 mm B.T  + 
12 sec 
Arterial + 
25 sec 
Venous + 
100 sec 
 
Legend: 
MDCT: multidetector Computer tomography 
B.T: bolus tracking 
Single slice CT: Hi Speed (GE Medical Systems; Milwaukee, WI) 
4-slice MDCT: Light Speed Plus (GE Medical Systems) 
64-slice MDCT: Light Speed VCT 64 (GE Medical Systems) 
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Table 2 – Percentage of tumor necrosis at pathology 
 
% necrosis at pathology Variables 
100 90-99 50-90 <50 0 
P 
n. patients (%) 60 (33.7) 38 (21.4) 45 (25.3) 20 (11.2) 15 (8.4)  
Age (years) 54.8± 7 56.2± 6.8 56.5 ±5.5 56.5± 5.5 55.4± 5.9 .66 
M/F (n) 46/14 34/4 41/4 19/1 15/0 .04 
n. nodules 1.5 ±0.8 2.0±0.9 2.4±1.6 3.0±2.0 1.7±0.7 <.0001 
RECIST diameter 
(mm) 
36.2 ±21.3 49.0 ±26.6 54.9±31.5 60.9 ±28 35.2± 15.2 .0002 
Largest nodule 
diameter (mm) 
29.2±15.3 34.4±17.7 31.9± 13.2 30.4± 11.7 26.1 ±13.8 .33 
Lipiodol-TACE / 
DEB-TACE 
53/7 33/5 39/6 18/2 13/2 .99 
TACE-LT (days) 195± 119 168± 106 152± 93 132 ±166 155 ±150 .22 
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Table 3 – CT-pathology correlation: nodule-by-nodule analysis. 
 
% necrosis at pathology CT 
(mRECIST) 
n. 
nodules 100 90-99 50-90 <50 0 
CR 157 98 
(62.4%) 
45 (28.7%) 8 
(5.1%) 
3 
(1.9%) 
3 
(1.9%) 
PR 73 13 
(17.8%) 
20 (27.4%) 24 (32.9%) 5 
(6.8%) 
11 (15.1%) 
SD 72 1 
(1.4%) 
0 2 
(2.8%) 
11 
(15.2%) 
58 (80.6%) 
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Table 4 – CT-pathology correlation: patient-by-patient analysis 
The overall agreement was 69.9% (119/178 patients, k=0.44). 
 
% necrosis at pathology CT 
(mRECIST) 
n. 
patients 100 90-99 50-90 <50 0 
CR 86 51 
(59.3%) 
26 (30.2%) 7 
(8.2%) 
2 
(2.3%) 
0 
 
PR 52 9 (17.3%) 11 (21.1%) 28 (53.9%) 4 
(7.7%) 
0 
SD 23 0 0 2 
(8.7%) 
9 
(39.1%) 
12 
(52.2%) 
PD 17 0 
 
0 9 
(52.9%) 
5 
(29.4%) 
3  
(17.7%) 
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Table 5 – CT-pathology correlation: responders versus non-responders 
 
Pathology necrosis (%) CT 
(mRECIST) 
n. patients 
50-100 <50 
Responders (CR+PR) 138 132  
(95.7%) 
6  
(4.3%) 
Non-responders 
(SD+PD) 
40 11  
(27.5%) 
29 
(72.5%) 
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Fig. 1: complete response after Lipiodol-TACE 
CT examination performed one month after Lipiodol-TACE in a cirrhotic patient with a 
single HCC nodule in the right liver lobe demonstrates the dense and homogeneous 
accumulation of Lipiodol in the nodule (A), with no evidence of arterial enhancement 
(B) or wash-out in the portal (C) and delayed (D) phases. The finding was interpreted as 
complete response according to mRECIST. Patient was transplanted two months after 
TACE. At pathology, 100% necrosis was found (E). 
A.                                                   B. 
 
C.                                                  D. 
 
E. 
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Fig. 2: progressive disease after Lipiodol-TACE 
CT examination performed six months after Lipiodol-TACE of a single nodule in the 
left liver lobe demonstrates dense and homogeneous accumulation of Lipiodol in the 
nodule (A), with no evidence of arterial enhancement (B) or wash-out in the delayed (C) 
phases. The finding was interpreted as complete response according to mRECIST. 
However, a new 1 cm lesion was found in segment 2 with typical enhancement pattern 
for HCC (wash-in the arterial phase, D, wash-out in the portal phase, E). At pathology, 
minimal residual viable tumor (90-99% necrosis) was present peripherally to the treated 
nodule (F) and the new 1 cm lesion was classified as HCC. Thus progressive disease, 
according to mRECIST, was associated to an estimated 50-90% necr osis at pathology. 
A.                                            B.                                           C. 
 
 
D.                                                    E. 
  
F. 
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